First Tracks Biotherapeutics to disclose Phase 1b trial data for celiac disease candidate
First Tracks Biotherapeutics will present top-line data from its Phase 1b study of ANB033, a CD122 antagonist, focusing on the prevention of mucosal damage in celiac disease patients.
San Diego-based biotechnology firm First Tracks Biotherapeutics (Nasdaq: TRAX) is set to release data from the first cohort of its global Phase 1b clinical trial of ANB033. The study evaluates the investigational drug, a CD122 antagonist, in a gluten-challenge setting designed to measure its efficacy in preventing mucosal damage associated with celiac disease.
The findings are scheduled for release on October 12, 2026, accompanied by an investor webcast. ANB033 represents a core component of the company’s development pipeline, which also includes treatments for eosinophilic esophagitis and rheumatoid arthritis.
First Tracks Biotherapeutics specializes in antibody therapies targeting immune pathways involved in inflammatory conditions. The company's progress with ANB033 is part of a broader industry effort to identify pharmacological interventions for celiac disease, a condition currently managed primarily through strict dietary avoidance of gluten.